Abstract
Introduction: Accidental and suicidal exposures to organophosphorus compounds (OPC) are frequent. The inhibition of esterases by OPC leads to an endogenous ACh poisoning. Recently, the FDA approved, based on animal experiments, for military combat medical use oral pyridostigmine (PSTG) for pre-exposure treatment of soman; the concept is to block the cholinesterase reversibly using the carbamate pyridostigmine in order to deny access to the active site of the enzyme to the irreversible inhibitor (OPC) on subsequent exposure. We have shown previously that tiapride (TIA) is in vitro a weak inhibitor of AChE. We also have shown recently that in rats coadministration of TIA with the organophosphate paraoxon significantly decreases mortality without having an impact on red blood cell cholinesterase (RBC-AChE) activity.
Purpose of the study: To establish in a prospective, non-blinded study in a rat model of acute high dose OPC (paraoxon; POX) exposure the ideal point in time for TIA pre-treatment administration and to correlate it with measured TIA plasma levels.
Material and Methods: There were six groups of rats in each cycle of the experiment and each group contained six rats. The procedure was repeated twelve times (cycles) (n = 72 for each arm; half male and half female). All substances were applied ip.
All groups (1–6) received 1 μMol POX (≈LD75); groups 1–5 also received 50 μMol TIA at different points in time.
-
Group 1 (G1): TIA 120 min before POX
-
Group 2 (G2): TIA 90 min before POX,
-
Group 3 (G3): TIA 60 min before POX,
-
Group 4 (G4): TIA 30 min before POX,
-
Group 5 (G5): TIA & POX simultaneously,
-
Group 6 (G6): POX only.
The animals were monitored for 48 hours and mortality/survival times were recorded at 30 min, 1, 2, 3, 4, 24 and 48 h. AChE activities were determined at 30 min, 24 and 48 h in surviving animals.
Statistical analysis was performed on the mortality data, cumulative survival times and enzyme activity data. Mortality data was compared using Kaplan-Meier plots. Cumulative survival times and enzyme activites were compared using the Mann-Whitney rank order test. No Bonferroni correction for multiple comparisons was applied and an α ≤ 0.05 was considered significant.
Results: Mortality is statistically significantly reduced by TIA pre-treatment at all points-in-time. Highest protection is achieved if TIA is given 90 to 0 min before OPC exposure. The reduction in mortality is not correlated to TIA plasma levels (Cmax ≈ 120 min post ip-administration). TIA pre-treatment is not affecting AChE activity regardless of the timing of administration.
Conclusion: The lack of correlation between TIA plasma levels and degree of mortality reduction as well as the lack of protective effect on enzyme activity seem to indicate that the site of action of TIA is not the blood. While our hypothesis that TIA would protect AChE in a pyridostigmine-like manner (via protection of the enzyme) could not be confirmed, the reduction in mortality with TIA pre-treatment is nevertheless of potential interest. (Mol Cell Biochem xxx: 1–8, 2005)
Similar content being viewed by others
References
Levine R: Recognized and possible effects of pesticides in humans. In WJ Hayes, ER Laws (ed.), Handbook of Pesticide Toxicology, General Principles, Academic Press. San Diego, vol. 1, pp. 275–360, 1991
Bajgar J: Organophosphates/nerve agent poisoning: Mechanism of action, diagnosis, prophylaxis and treatment. Advances Clin Chem 38: 151–216, 2004
Jeyaratnam J: Acute pesticide poisoning: a major global health problem. World Health Stat Q 43: 139–144, 1990
Karalliedde L: Organophosphourus poisoning and anaesthesia. Anaesthesia 54: 1073–1088, 1999
Namba T: Cholinesterase inhibition by organophospourus compounds, and its clinical effects. Bull WHO 44: 289–307, 1971
Namba T, Nolte CT, Jackrel J, Grob D: Poisoning due to organophosphate insecticides: acute and chronic manifestations. Am J Med 50: 457–492, 1971
Zoch E: Die Wirkung organischer Phosphorsäureester bzw. Phosphorsäureester auf versch. Enzyme Arzneim Forschung 21: 181–187, 1971
Petroianu G, Toomes LM, Petroianu A, Bergler W, Rufer R: Control of blood pressure, heart rate and haematocrit during high-dose intravenous Paraoxon exposure in mini pigs. J Appl Toxicol 18: 293–298, 1998
Johnson MK, Jacobsen D, Meredith TJ, Eyer P, Heath AJ, Ligtenstein DA, Marrs TC et al.: Evaluation of antidotes for poisoning by organophosphourus pesticides. Emerg Med 12: 22–37, 2000
van Helden HP, Busker RW, Melchers BP, Bruijnzeel PL: Pharmacological effects of oximes: how relevant are they? Arch Toxicol 70: 779–786, 1996
Peter JV, Cherian AM: Organic insecticides. Anaesth Intensive Care 28: 11–21, 2000
Worek F, Szinicz L, Eyer P, Thiermann H. Evaluation of oxime efficacy in nerve agent poisoning: development of a kinetic-based dynamic model. Toxicol Appl Pharmacol. 2005 May 16 [Epub ahead of print]
Petroianu GA, Arafat K, Kuca K, Kassa J: Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: in vitro reactivation of red blood cell acetylcholinesterase inhibitied by paraoxon. J Appl Toxicol 2005 Sep 29 [Epub ahead of print]
Gordon JJ, Leadbeater L, Maidment MP: The protection of animals against organophosphate poisoning by pretreatment with a carbamate. Toxicol. Appl. Pharmacol 43: 207–216, 1978
Wiener SW, Hoffman RS: Nerve agents: a comprehensive review. J Intensive Care Med 19: 22–37, 2004
Marino MT, Schuster BG, Brueckner RP, Lin E, Kaminskis A, Lasseter KC: Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans. J Clin Pharmacol 38: 227–235, 1998
Fontaine J, Reuse J: The effects of substituted benzamides on frog rectus abdominis. Eur J Pharmacol 68: 55–60, 1980
Petroianu GA, Arafat K, Schmitt A, Hasan MY: Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. J Appl Toxicol 25: 60–67, 2005
Petroianu GA, Hasan MY, Nurulain SM, Arafat K, Shafiullah M, Naseer OP: Protective agents in acute high dose organophosphate exposure: comparison of ranitidine with pralidoxime in rats. J Appl Toxicol 25: 68–73, 2005
Petroianu GA, Arafat K, Schmitt A, Hasan MY: Weak inhibitors protect cholinesterases from strong inhibitors (dichlorvos): in vitro effect of tiapride. Internat J Toxicol 24: 79–86, 2005
Petroianu GA, Hasan MY, Nurulain SM, Arafat K, Sheen R, Saleh A, Schmitt A: Protective agents in acute high dose exposure to organophosphates: comparison of metoclopramide and tiapride with pralidoxime in rats. Anesth Analg 100: 382–386, 2005
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Amer Statist Assoc 53: 457–81, 1958
Dawson JD, Lagakos SW: Size and power of two sampled tests of repeated measures data. Biometrics 49: 1022–1032, 1993
Worek F, Mast U, Kiderlen D, Diepold C, Eyer P: Improved determination of acetylcholinesterase activity in human whole blood. Clin Chim Acta 288: 73–90, 1999
Ellman GL, Courtney KD, Feather-Stone RM, Andres V Jr: A new and rapid colorimetric determination of acetyl-cholinesterase activity. Biochem Pharmacol 7: 88–95, 1961
van Kampen EJ, Zijlstra WG: Standardization of hemoglobinometry II. The hemoglobincyanide method. Clin Chim Acta 6: 538–544, 1961
Dart RC, Goldfrank LR, Chyka PA, Lotzer D, Woolf AD, McNally J, Snodgrass WR, Olson KR, Scharman E, Geller RJ, Spyker D, Kraft M, Lipsy R: Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann Emerg Med 36: 126–132, 2000
Petroianu G, Arafat K, Kosanovic M, Saleh A, Camasamudram V, Hassan MY: In vitro protection of RBC acetylcholinesterase by metoclopramide from inhibition by organophosphates (paraoxon and mipafox). J Appl Toxicol 23: 447–451, 2003
Hasan MY, Nurulain SM, Arafat K, Naseer OP, Petroianu GA: In-vivo metoclopramide protection of cholinesterase from paraoxon inhibition: direct comparison with pralidoxime in sub-chronic low dose exposure. J Appl Toxicol 24: 257–260, 2004
Delmeire F: Tiapridal. Acta Psychiatr Belg 80: 191–201, 1980
Satoh H, Nakanishi H, Shirakawa K, Kohjimoto Y, Kuwaki T, Ono T, Shibayama F: Comparative study of tiapride and neuroleptics with anti-dopamine activity on convulsive seizure in mice. Jpn J Pharmacol 43: 27–32, 1987
Warter JM, Vergnes M, Depaulis A, Tranchant C, Rumbach L, Micheletti G, Marescaux C: Effects of drugs affecting dopaminergic neurotransmission in rats with spontaneous petit mal-like seizures. Neuropharmacology 27: 269–274, 1988
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Petroianu, G.A., Hasan, M.Y., Nurulain, S.M. et al. Tiapride pre-treatment in acute exposure to paraoxon: Comparison of effects of administration at different points-in-time in rats. Mol Cell Biochem 285, 79–86 (2006). https://doi.org/10.1007/s11010-005-9057-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-005-9057-7